Trastuzumab Deruxtecan: First Approval

Trastuzumab deruxtecan (ENHERTU ® ), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2020-04, Vol.80 (5), p.501-508
1. Verfasser:	Keam, Susan J.
Format:	Artikel
Sprache:	eng
Schlagworte:	AdisInsight Report Agreements Antibodies Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Breast cancer Camptothecin - analogs & derivatives Camptothecin - chemistry Camptothecin - pharmacology Cell cycle Clinical trials Collaboration Colorectal cancer Colorectal carcinoma Deoxyribonucleic acid DNA DNA topoisomerase DNA Topoisomerases, Type I - metabolism Drug Approval Drug dosages Enzymes ErbB-2 protein Gastric cancer Humans Immunoconjugates - chemistry Immunoconjugates - pharmacology Immunotherapy Internal Medicine Lung cancer Medicine Medicine & Public Health Metastases Metastasis Monoclonal antibodies Neoplasms - drug therapy Neoplasms - metabolism Non-small cell lung carcinoma Patients Pharmacology/Toxicology Pharmacotherapy Phosphorylation Small cell lung carcinoma Solid tumors Targeted cancer therapy Topoisomerase I Inhibitors - chemistry Topoisomerase I Inhibitors - pharmacology Trastuzumab Trastuzumab - chemistry Trastuzumab - pharmacology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!